Literature DB >> 2123742

Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

B Gansbacher1, R Bannerji, B Daniels, K Zier, K Cronin, E Gilboa.   

Abstract

Retroviral vectors were used to introduce the gamma-interferon (IFN-gamma) gene into CMS-5 cells, a weakly immunogenic tumor of BALB/c origin. After selection in G418-containing medium, colonies were isolated, cloned, and expanded to cell lines. IFN-gamma secretion was assessed using a bioassay and enzyme-linked immunosorbent assay, and high (25 units/ml) and low (5 units/ml) IFN-gamma producers were isolated. Tumor growth was followed after intradermal injection, and spleen cells were isolated at different time points. IFN-gamma secretion by tumor cells abrogated their tumorigenicity and induced a persistent and specific antitumor immunity. In contrast to the normally observed cellular immunosuppression in unmodified CMS-5 tumor-bearing mice, IFN-gamma-producing tumors induced a long lasting state of T-cell immunity, as judged by rejection of a CMS-5 tumor challenge and persistence of specific cytotoxic activity in the spleen cell population. High levels of tumor-specific cytotoxic activity could also be detected if IFN-gamma-secreting tumor cells, but not unmodified CMS-5 cells, were used as targets at a time point when immunosuppression was usually seen. These studies highlight the potential advantages of localized IFN-gamma secretion to induce potent antitumor immune responses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2123742

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Transduction of human hepatocellular carcinoma cells with human alpha-interferon gene via retroviral vector.

Authors:  Shu-Bing Qian; Shi-Shu Chen
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

Review 2.  Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Authors:  N P Restifo; Y Kawakami; F Marincola; P Shamamian; A Taggarse; F Esquivel; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10

3.  In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant.

Authors:  T Ohira; Y Ohe; Y Heike; E R Podack; K J Olsen; K Nishio; M Nishio; Y Miyahara; Y Funayama; H Ogasawara
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  Ganciclovir mediated regression of rat brain tumors expressing the herpes simplex virus thymidine kinase imaged by magnetic resonance.

Authors:  A Maron; T Gustin; I Mottet; R Demeure; J N Octave
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

5.  In vivo cytokine gene transfer by gene gun reduces tumor growth in mice.

Authors:  W H Sun; J K Burkholder; J Sun; J Culp; J Turner; X G Lu; T D Pugh; W B Ershler; N S Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

Authors:  J H Sampson; G E Archer; D M Ashley; H E Fuchs; L P Hale; G Dranoff; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

7.  Role of endogenous interferon gamma in murine tumor growth and tumor necrosis factor alpha antitumor efficacy.

Authors:  G M Doherty; H R Alexander; M J Merino; D J Venzon; J A Norton
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

8.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

Authors:  A A Hurwitz; T F Yu; D R Leach; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

9.  In situ cytokine production by breast cancer tumor-infiltrating lymphocytes.

Authors:  B J Camp; S T Dyhrman; V A Memoli; L A Mott; R J Barth
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

Review 10.  IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells.

Authors:  K S Zier; B Gansbacher
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.